Keman Zhang

Cleveland Clinic — United States

Medicine · Health Sciences

15h-index704citations72works11.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Lymphoblastic Leukemia research(15), Immune Cell Function and Interaction(13), CAR-T cell therapy research(13), Polyamine Metabolism and Applications(13), Cancer Immunotherapy and Biomarkers(9)

Publications72 total

Notch1 blockade by a novel, selective anti-Notch1 neutralizing antibody improves immunotherapy efficacy in melanoma by promoting an inflamed TME
Journal of Experimental & Clinical Cancer Research·2024· 4 citedOpen Access
855 LRIG1 engages ligand VISTA to impede T cell activation and enable tumor immune evasion
Regular and Young Investigator Award Abstracts·2024Open Access
568 Examine the expression of leucine-rich repeats and immunoglobulin-like domains protein-1 (LRIG1) in human tumor-infiltrating lymphocytes
Regular and Young Investigator Award Abstracts·2024Open Access
Protocol for analyzing arginase I expression in tumor-associated myeloid-derived suppressor cells from murine colon cancer using flow cytometry
STAR Protocols·2024· 1 citedOpen Access
LRIG1 engages ligand VISTA and impairs tumor-specific CD8 <sup>+</sup> T cell responses
Science Immunology·2024· 35 citedOpen Access
Abstract 1358: Elucidating the contribution of T cell-intrinsic VISTA to the suppression of antitumor T cell immunity
Cancer Research·2024
VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms
Cell Reports·2024· 38 citedOpen Access
935 VISTA regulates the differentiation of myeloid-derived suppressor cells by STAT3-dependent modulation of arginase-1 and iNOS expression and mitochondrial function
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
Figure 5S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Figure Legends from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
2023Open Access
Figure 4S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
2023Open Access
Data from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
2023Open Access
Figure 2S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
2023Open Access
Figure 4S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
2023Open Access
Figure 3S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
2023Open Access
Figure 5S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
2023Open Access
Data from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
2023Open Access
Figure 6S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
2023Open Access
Figure 1S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
2023Open Access
Figure 3S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Reshmi Parameswaran(23), Yorleny Vicioso(21), Abhishek Asthana(16), Derek P. Wong(14), Parameswaran Ramakrishnan(10), Rose Beck(10), Barbara Bedogni(9), Hieu Minh Ta(9), Hermann Gram(9), John J. Letterio(8), Timothy A. Chan(7), Abhishek Asthana(6), Amin Zakeri(6), Tyler Alban(6), Jingfeng Sha(5), Marian L. Harter(5), Prerana Bangalore Parthasarathy(5), Cassandra Gilmour(5), Khvaramze Shaverdashvili(4), Poki Wong(4)